SOLESENCE, INC. — Director's Dealing 2024

Sep 25, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2024-09-23

Reporting Person: WHITMORE R JANET (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-23	Common Stock	P	26000	$1.59	Acquired	1979909	Direct
2024-09-24	Common Stock	P	23150	$1.60	Acquired	2003059	Direct
2024-09-24	Common Stock	P	200	$1.59	Acquired	2003259	Direct
2024-09-24	Common Stock	P	550	$1.55	Acquired	2003809	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Deferred Common Stock	$		Common Stock (20030)	20030	Direct
Common Stock (right to purchase)	$0.9	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.05	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.18	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$0.84	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.85	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.10	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$0.99	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$0.68	2027-02-21	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.82	2028-05-23	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.45	2027-06-18	Common Stock (6667)	6667	Direct
Common Stock (right to purchase)	$4.17	2028-12-28	Common Stock (20000)	20000	Direct
Common Stock (right to purchase)	$1.165	2029-12-20	Common Stock (20000)	20000	Direct
Common Stock (right to purchase)	$0.61	2030-12-27	Common Stock (12600)	12600	Direct

Footnotes

F1: The purchase of these 26,000 shares was made through 10 trades, all at $1.59/share. The trades were made throughout the day, with the smallest purchases (3 different transactions) being 100 shares and the largest being 6,000 shares. The average purchased amount among these transactions was 2,600 shares.

F2: The purchase of these 23,150 shares was made through 3 trades, all at $1.60/share. The trades amounted to 3,000, 20,050, and 100 shares, respectively.

F3: Each share of deferred common stock represents the right to receive one share of common stock.

F4: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.

F5: Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 20,030 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensaion Plan.

F6: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. Two-thousand shares were issued with an exercise price of $0.90, 2,000 were issued with an exercise price of $1.05, 2,000 were issued with an exercise price of $1.18, 2,000 were issued with an exercise price of $0.84, 2,000 were issued with an exercise price of $1.85. 2,000 were issued with an exercise price of $1.10, and 2,000 were issued with an exercise price of $0.99.

F7: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.